EGFR and lung cancer: Non-small cell lung cancer (NSCLC) represents approximately 85% of lung cancer cases, with most patients in Western populations having wild-type or unknown status for epidermal growth factor receptor (EGFR) and do not present anaplastic lymphoma kinase gene rearrangement [3].